000307560 001__ 307560
000307560 005__ 20260223120900.0
000307560 0247_ $$2doi$$a10.1200/OP-25-01017
000307560 0247_ $$2pmid$$apmid:41499731
000307560 0247_ $$2ISSN$$a2688-1527
000307560 0247_ $$2ISSN$$a1554-7477
000307560 0247_ $$2ISSN$$a1935-469X
000307560 0247_ $$2ISSN$$a2688-1535
000307560 037__ $$aDKFZ-2026-00056
000307560 041__ $$aEnglish
000307560 082__ $$a610
000307560 1001_ $$00000-0002-0414-9561$$aMulder, Renée L$$b0
000307560 245__ $$aInternational Guideline Harmonization Group Recommendations for Breast Cancer Surveillance in Childhood, Adolescent, and Young Adult Cancer Survivors After Anthracyclines.
000307560 260__ $$aAlexandria, Va.$$bAmerican Society of Clinical Oncology$$c2026
000307560 3367_ $$2DRIVER$$aarticle
000307560 3367_ $$2DataCite$$aOutput Types/Journal article
000307560 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1767880016_3506153$$xReview Article
000307560 3367_ $$2BibTeX$$aARTICLE
000307560 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000307560 3367_ $$00$$2EndNote$$aJournal Article
000307560 500__ $$aISSN 2688-1535 / epub
000307560 520__ $$aWith new evidence emerging about breast cancer risk following anthracycline chemotherapy, the International Late Effects of Childhood Cancer Guideline Harmonization Group updated the evidence and breast cancer surveillance recommendations for female childhood, adolescent, and young adult (CAYA) cancer survivors.The Grading of Recommendations Assessment, Development, and Evaluation methodology was used to incorporate new knowledge and refine breast cancer surveillance recommendations. The guideline panel updated the systematic literature review and revised recommendations based on new evidence, clinical judgment, and assessments of benefits and harms of surveillance, ensuring adaptability across various health care systems.The literature update revealed new findings on the effects of anthracyclines on breast cancer risk in female CAYA cancer survivors. Moderate-quality evidence shows no significant association between doxorubicin doses <100 mg/m2 and breast cancer risk. High-quality evidence indicates a statistically significant but weak association between breast cancer risk and 100-199 mg/m2 doxorubicin (relative risk, <2) and a moderate breast cancer risk (relative risk, 2-4) for those treated with ≥200 mg/m2 in the absence of radiotherapy exposing breast tissue (chest radiation). Routine breast cancer surveillance after ≥200 mg/m2 doxorubicin in the absence of chest radiation is reasonable from age 30 years onward or ≥8 years from exposure (whichever occurs last). Due to inconclusive evidence, no recommendation could be formulated for routine breast cancer surveillance after daunorubicin, epirubicin, or idarubicin, in the absence of chest radiation.The newly identified evidence on breast cancer risk after anthracyclines supports changes in the 2019 recommendations regarding breast cancer surveillance for survivors treated with ≥200 mg/m2 doxorubicin without chest radiation.
000307560 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000307560 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000307560 7001_ $$00000-0002-8886-6532$$avan Dalen, Elvira C$$b1
000307560 7001_ $$00000-0002-2647-2677$$aTeepen, Jop$$b2
000307560 7001_ $$00000-0001-6984-2407$$aHudson, Melissa M$$b3
000307560 7001_ $$00000-0003-0742-1740$$aConstine, Louis S$$b4
000307560 7001_ $$00000-0002-7755-5683$$aBhatia, Smita$$b5
000307560 7001_ $$00000-0003-3319-5652$$aLandier, Wendy$$b6
000307560 7001_ $$aLevitt, Gill$$b7
000307560 7001_ $$00000-0001-8080-5674$$aWallace, W Hamish$$b8
000307560 7001_ $$00000-0002-5871-1484$$avan Leeuwen, Flora E$$b9
000307560 7001_ $$0P:(DE-He78)179d42bde859e38f13bb914c552cc4e5$$aRonckers, Cécile$$b10$$udkfz
000307560 7001_ $$00000-0001-9394-6206$$aHenderson, Tara O$$b11
000307560 7001_ $$00000-0002-2850-8450$$aMoskowitz, Chaya S$$b12
000307560 7001_ $$00000-0003-4668-9176$$aFriedman, Danielle N$$b13
000307560 7001_ $$00000-0001-8428-7421$$aNg, Andrea K$$b14
000307560 7001_ $$aJenkinson, Helen C$$b15
000307560 7001_ $$00000-0002-1236-9089$$aDemoor-Goldschmidt, Charlotte$$b16
000307560 7001_ $$aBarnea, Dana$$b17
000307560 7001_ $$00000-0003-2781-9983$$aEhrhardt, Matthew J$$b18
000307560 7001_ $$avan As, Jorrit W$$b19
000307560 7001_ $$00000-0003-2253-2115$$avan der Pal, Helena J$$b20
000307560 7001_ $$00000-0002-2724-7404$$aYeh, Jennifer M$$b21
000307560 7001_ $$00000-0002-1162-675X$$aSkinner, Roderick$$b22
000307560 7001_ $$aKremer, Leontien C M$$b23
000307560 7001_ $$00000-0003-0806-7894$$aOeffinger, Kevin C$$b24
000307560 773__ $$0PERI:(DE-600)3005549-0$$a10.1200/OP-25-01017$$gp. OP-25-01017$$pnn$$tJCO oncology practice$$vnn$$x2688-1527$$y2026
000307560 8564_ $$uhttps://inrepo02.dkfz.de/record/307560/files/mulder-et-al-2026-international-guideline-harmonization-group-recommendations-for-breast-cancer-surveillance-in.pdf$$yOpenAccess
000307560 8564_ $$uhttps://inrepo02.dkfz.de/record/307560/files/mulder-et-al-2026-international-guideline-harmonization-group-recommendations-for-breast-cancer-surveillance-in.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000307560 909CO $$ooai:inrepo02.dkfz.de:307560$$popenaire$$popen_access$$pdnbdelivery$$pdriver$$pVDB
000307560 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)179d42bde859e38f13bb914c552cc4e5$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000307560 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000307560 9141_ $$y2026
000307560 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000307560 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000307560 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-18
000307560 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJCO ONCOL PRACT : 2022$$d2024-12-18
000307560 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000307560 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000307560 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000307560 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000307560 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-18
000307560 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000307560 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-18
000307560 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000307560 9201_ $$0I:(DE-He78)C190-20160331$$kC190$$lCAYA Cancer Survivorship Forschung$$x0
000307560 980__ $$ajournal
000307560 980__ $$aVDB
000307560 980__ $$aUNRESTRICTED
000307560 980__ $$aI:(DE-He78)C190-20160331
000307560 9801_ $$aFullTexts